The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus

Autoimmunity Reviews

Volumn 10, Issue 2, 2010, Pages 108-111

  Galarza Maldonado, Claudio ^a   Kourilovitch, María R ^a,b   Molineros, Julio E ^c   Cardiel, Mario H ^d   Zurita, Luis ^e   Soroka, Nikolay F ^f   Yagur, Viktor Y ^f   Doukh, Natalia ^g   Cervera, Ricard ^b  

^a Hospital Monte Sinai   (Ecuador)

^b HOSPITAL CLÍNIC   (Spain)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^d HOSPITAL GENERAL DR MIGUEL SILVA   (Mexico)

^e Hospital Clínica Alcívar   (Ecuador)

^f BELARUSIAN STATE MEDICAL UNIVERSITY   (Belarus)

^g UNIVERSIDAD DE LAS AMÉRICAS   (Ecuador)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

BRONCHITIS; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DEATH; DISEASE ACTIVITY; DRUG DOSE REDUCTION; ETHNIC GROUP; HEMODIALYSIS; HERPES ZOSTER; HISPANIC; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; RASH; REVIEW; SCORING SYSTEM; SEROLOGY; SINGLE DRUG DOSE; SOUTH AND CENTRAL AMERICA; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ECUADOR; HUMANS; HYDROXYCHLOROQUINE; LATIN AMERICA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYCOPHENOLIC ACID; PREDNISONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 78650416364     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.08.012     Document Type: Review

References (38)

1. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., van Zeben D., Kerstens P.J., Hazes J.M., et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007, 146:406-415.
2. Landewé R.B., Boers M., Verhoeven A.C., Westhovens R., van de Laar M.A., Markusse H.M., et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002, 46:347-356.
3. Mosca M., Ruiz-Irastorza G., Khamashta M.A., Hughes G.R.V. Treatment of systemic lupus erythematosus. Int Immunopharmacol 2001, 1:1065-1075.
4. O'Neill S.G., Schrieber L. Immunotherapy of systemic lupus erythematosus. Autoimmun Rev 2005, 4:395-402.
5. Dooley M.A., Ginzler E.M. Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents. Rheum Dis Clin North Am 2006, 32:91-102.
6. Galarza C., Valencia D., Tóbon G.J., Zurita L., Mantilla R.D., Pineda-Tamayo R., et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?. Clin Rev Allergy Immunol 2008, 34:124-128.
7. Lu T.Y., Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009, 61:482-487.
8. García-Carrasco M., Mendoza-Pinto C., Sandoval-Cruz M., Soto-Vega E., Beltrán-Castillo A., Jiménez-Hernández M., et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus 2009, 18:1-7.
9. Terrier B., Amoura Z., Ravaud P., Hachulla E., Jouenne R., Combe B., et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French Autoimmunity and Rituximab Registry. Arhtritis Rheum 2010, 62:2458-2466.
10. Guzman R. B-cell depletion in autoimmune diseases: advances in autoimmunity. Autoimm Rev 2009, 8:85-90.
11. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233.
12. Furie R., Looney R.J., Rovin B., Latinis K.M., Appel G., Sánchez-Guerrero J, et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study [abstract no. 1149]. American College of Rheumatology National Meeting 2009; 2009 Oct 17-21; Philadelphia (PA) 2009.
13. Ramos-Casals M., Díaz-Lagares C., Khamashta M.A. Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al. Arthritis Rheum 2009, 61:1281-1282.
14. Looney R.J. B cell-targeted therapies for systemic lupus erythematosus. An update on clinical trial data. Drugs 2010, 70:529-540.
15. Marrill J.T., Buyon J.P. Rituximab: wanted dead or alive. Arthritis Rheum 2010, 62:2188-2191.
16. Soriano E.R., Galarza-Maldonado C., Cardiel M.H., Pons-Estel B.A., Massardo L., Caballero-Uribe C.V., et al. Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context. Rheumatology 2008, 47:1097-1099.
17. Guzman J., Cardiel M.H., Arce-Salinas A., Sanchez-Guerrero J., Alarcon-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992, 19:1551-1558.
18. Uribe A.G., Vilà L.M., McGwin G., Sánchez M.L., Reveille J.D., Alarcón G.S. The Systemic Lupus Activity Measure-Revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a Modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol 2004, 31:10.
19. Mosca M, Shoenfeld Y, Bombardieri S: Systemic lupus erythematosus: treatment. EULAR on-line course on rheumatic diseases-module no. 18; 2010.
20. Hoes J.N., Jacobs J.W.G., Boers M., Boumpas D., Buttgereit F. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007, 66:1560-1567.
21. The Canadian Hydroxychloroquine Study Group, a randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Eng J Med 1991, 324:150-154.
22. The Canadian Hydroxychloroquine Study Group, a long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus 1998, 7:80-85.
23. Ho K.T., Ahn C.W., Alarcon G.S., Baethge B.A., Tan F.K., Roseman J., et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology 2005, 44:1303-1307.
24. Tam L.S., Gladman D.D., Hallett D.C., Rahman P., Urowitz M.B. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000, 27:2142.
25. Shinjo S.K., Bonfa E., Wojdyla D., Borba E.F., Ramírez L.A., Scherbarth H.R., et al. Antimalarial treatment may have a time-dependent effect on lupus survival. Data from a multinational Latin American inception cohort. Arthritis Rheum 2010, 62:855-862.
26. Sarabi Z.S., Chang E., Bobba R., Ibanez D., Gladman D., Urowitz M., et al. Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. Arthritis Rheum 2005, 53:609-612.
27. Jung H., Bobba R., Su J., Shariati-Sarabi Z., Gladman D.D., Urowitz M., et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010, 62:863-868.
28. Iaccarino L., Rampudda M., Canova M., Della Libera S., Sarzi-Puttinic P., Doria A. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases?. Autoimmun Rev 2007, 6:190-195.
29. Appel G.B., Contreras G., Dooley M.A. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009, 20:1103-1111.
30. Whitmire J.K., Asano M.S., Kaech S.M., Sarkar S., Hannum L.G., Shlomchik M.J., et al. Requirement of B cells for generating CD4+ T cell memory. J Immunol 2009, 182:1868-1876.
31. Bouaziz J.-D., Yanaba K., Venturi G.M., Wang Y., Tisch R.M., Poe J.C., et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci USA 2007, 104:20878-20883.
32. Liu K., Mohan C. Altered B-cell signaling in lupus. Autoimmun Rev 2009, 8:214-218.
33. Jenks S.A., Sanz I. Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev 2009, 8:209-213.
34. Cornec D., Avouac J., Youinou P., Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev 2009, 8:515-519.
35. Gerli R., Nocentini G., Alunno A., Bocci E.B., Bianchini R., Bistoni O., et al. Identification of regulatory T cells in systemic lupus erythematosus. Autoimmun Rev 2009, 8:426-430.
36. Wilk E., Witte T., Marquardt N., Horvath T., Kalippke K., Scholz K., et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum 2009, 60:3563-3571.
37. Ramos-Casals M., Diaz-Lagares C., Soto-Cardenas M.J., Brito-Zeron P., Cuadrado M.J., Sanna G., et al. Rituximab therapy in lupus nephritis: current clinical evidence. Clin Rev Allergy Immunol Apr 24 2010, [Epub ahead of print].
38. García-Carrasco M., Jiménez-Hernández M., Escárcega R.O., Mendoza-Pinto C., Galarza-Maldonado C., Sandoval-Cruz M., et al. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev 2009, 8:343-348.